Mechanisms of melanoma resistance to treatment with BRAF and MEK inhibitors by Bartnik, Ewa et al.
133
Review article
NOWOTWORY Journal of Oncology 
2019, volume 69, number 3–4, 133–141
DOI: 10.5603/NJO.2019.0025
© Polskie Towarzystwo Onkologiczne
ISSN 0029–540X
www.nowotwory.edu.pl
Mechanisms of melanoma resistance to treatment 
with BRAF and MEK inhibitors 
Ewa Bartnik1, Michał Fiedorowicz2, Anna M. Czarnecka2, 3
1Institute of Genetics and Biotechnology, Faculty of Biology, University of Warsaw, Poland 
2Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland
3Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute — Oncology Center, Warsaw, Poland
 Several mechanisms of resistance to inhibition of BRAF activity in melanoma cells have been described so far. Genetic 
studies have shown that mutations in MEK1 kinase (MAP kinase kinase), which result in constitutive activation of ERK kinase, 
result in resistance to treatment. Another mechanism of the acquired BRAF inhibition resistance is the accumulation of 
activating mutations in the NRAS oncogene, which drives the activation of CRAF. This in turn leads to a permanent activation 
of the signal transduction to MEK and ERK. Another important mechanism of resistance is the formation of variants of the 
BRAF V600E gene splicing, including variants that lack exons 4 to 8 containing the RAS-binding domain. The presence of 
the p61 BRAF V600E variant leads to the constitutive ERK signal, which is resistant to RAF inhibition. In addition, treatment 
resistance is affected by hyperactivation of tyrosine kinase receptors such as platelet-derived factor receptor β (PDFRβ), 
insulin-like growth factor 1 receptor (IGF-1R) and erythropoietin-producing hepatocellular receptors (EPH) – leading to 
the induction of the 3-phosphoinositol kinase pathway (PI3K) in patients treated with BRAF or MEK inhibitors. Another 
interesting path of BRAFi/MEKi resistance is over-expression of the epidermal growth factor receptor (EGFR) through ne-
gative feedback in patients treated with BRAF inhibitors (BRAFi) – EGFR is not normally expressed in untreated melanomas.
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Introduction
Before the discovery of activating mutations in the BRAF gene, 
melanoma was considered to be the skin cancer with the 
worst prognosis. Classical dacarbazine-based chemotherapy 
regimens provided few therapeutic options. In 2002, in a bre-
akthrough study conducted by the Cancer Genome Project 
at the Sanger Institute, BRAF [1] mutations were identified 
in over 60% of melanoma patients. Currently, melanoma is 
responsible for over 80% of skin neoplasm deaths, although 
its cases account for only 1% of all skin neoplasm cases. Until 
2011, when the Food and Drug Administration (FDA) approved 
vemurafenib (the first drug acting selectively on a specific 
mutant protein in the signalling pathway of BRAF/MEK), there 
was virtually no effective therapy for patients with melanoma 
with metastases. The group of drugs that include vemurafenib 
(as well as dabrafenib and encorafenib) is referred to as BRAF 
(BRAFi) protein inhibitors [2].
The RAS/MAPK pathway (fig. 1) is one of the best known 
pathways of signal transduction from the cell environment 
to the cell nucleus in which, as a result of the action of these 
signals, the transcription of genes associated with the pro-
cesses of cell growth, division and differentiation is initiated. 
It can be said that it is a cascade of phosphorylation of subse-
quent proteins (Ras-Raf-MEK-ERK), where an activated protein 
phosphorylates a subsequent protein and thus the signal is 
transmitted up to the transcription factors (among others 
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c-Myc and CREB). Activated Ras stimulates RAF kinase protein 
kinase activity, RAF kinase phosphorylates and activates MEK 
(MEK1 and MEK2), and MEK phosphorylates and activates 
mitogen-activated protein kinase (MAPK). RAF and ERK  (also 
known as MAPK) are serine/threonine protein kinases and MEK 
is a serine/tyrosine/threonine kinase. This signalling pathway is 
activated by growth factors, hormones and cytokines that inte-
ract with the membrane receptor with tyrosine kinase activity 
(RTK). As a result of these interactions, the membrane receptor 
is phosphorylated and binds several different proteins, which 
in turn transmit a signal to the RAS (rat sarcoma) protein. RAS 
protein then binds guanosine triphosphate, which activates 
it and in turn transmits the signal to the whole next cascade 
of protein kinases activated by mitogens (mitogen activated 
protein kinases – MAPK). The first protein in this pathway is RAF 
(rapidly accelerated fibrosarcoma protein): BRAF or CRAF. RAF 
proteins have serine/threonine kinase activity and phosphory-
late and activate MAPK kinase, also known as MEK – MAPK/ERK, 
which in turn phosphorylates another ERK kinase (extracellular 
signal regulated kinase), which after phosphorylation moves 
to the cell nucleus, where it activates target transcription fac-
tors through phosphorylation. Disturbances in this pathway 
can lead to neoplasms on the one hand, and several human 
malformations on the other [3].
Disturbances in this pathway, including oncogenic ones, 
may occur at different levels as a result of gene mutations 
– the RAS gene is one of the most frequently mutated onco-
genes in human cancers [4]. Disturbances in the whole RAS/ 
/MAPK pathway occur in 98% of melanomas [5]. About 50% of 
these cancers (but for comparison, only 7–10% of all cancers 
in general) have a mutation in the BRAF gene. On the other 
hand, 80–90% of these mutations are of the V600E missense 
type, where amino acid number 600 is glutamic acid and not 
valine found in wild-type protein. This mutation changes the 
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Figure 1. RAS pathway in melanoma cells
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conformation of BRAF protein, increasing its kinase activity, 
resulting in constitutive activation of the MAPK/ERK pathway. 
In the same place, but much less frequently, there are also other 
substitutions, e.g. V600K (7.8%), V600R (1%) (lysine and arginine 
substitution, respectively). In melanoma cells mutations also 
occur in other MAPK/ERK pathway genes, most often in the 
NRAS gene (13–25%) [6, 7].
It is worth mentioning that mutations in the BRAF gene 
do not depend on UV radiation and are not sufficient to cause 
melanoma. The oncogenesis process is the result of many 
mutations in different genes. There are also other mutations 
in melanoma, e.g. in tumor suppressor genes TP53, PTEN and 
CDKN2A, as well as in the telomerase gene promoter [5]. Also 
important for melanoma development are mutations indu-
ced by UV radiation, which are characterized by transitions of 
C->T nucleotides at the 3’ end of pyrimidine dimers [8], such 
mutations occur in the above mentioned cancer suppressor 
genes, the telomerase gene and in p16. However, the issue of 
mutations induced by UV is complicated, they are different 
in different melanomas and molecular classification is based 
more on mutations that are not caused by UV rays [5]. More-
over, it is not easy to determine whether a given mutation was 
caused by UV, and it is not always certain [9].
In molecular terms, melanomas can be classified into 4 
groups based on the mutations that occur in them: in RAS, in 
BRAF, in NF1, and the fourth group consists of so-called triple-
-negative melanomas [5, 10, 11]. It is interesting that in primary 
melanomas mutations in RAS and BRAF genes never occur 
simultaneously. As for the  MEK gene mutations (MAPK), there 
is no such good data as for mutations in many other genes, but 
since MEK inhibitors are also used in melanoma therapy toge-
ther with BRAF inhibitors, MAP2K1 mutations occur in 5.38% 
of patients with melanoma while MAPK1 mutations occur in 
1.77% of patients with melanoma. Mutations in specific MAPK 
genes are often criteria for inclusion in clinical trials with MEK 
inhibitors (MEKi) [12].
BRAF protein normally acts as a dimer, but the V600E 
mutation causes it to act as a monomer. Inhibitors used in 
melanoma therapy, such as vemurafenib, have an effect on 
this monomer. Approximately 20% of patients with the BRAF 
V600E mutation do not respond to this drug [6]. The reasons 
for this are complex and may be due, among other things, to 
the heterogeneity of the cancer – e.g. not all of its cells have 
a target mutation, or to the loss of certain cancer suppressor 
genes, such as PTEN and NF1, which cause primary resistance 
to BRAFi/MEKi [6]. 
Similarly, after a few months of using BRAFi, melanoma 
cells become resistant to therapy, which may have different 
causes. In general, mutations that cause resistance act by 
increasing the frequency of RAF dimerization, although the 
most common cause of such resistance is reactivation of BRAF/ 
/MEK or another pro-proliferative signal transduction pathway. 
This reactivation may pass through ERK or other proteins. The 
reactivation can also be done by activating other RAFs, e.g. 
ARAF and CRAF. Another signal transduction pathway, such as 
PI3K-AKT-mTOR, can also be activated in the process of creating 
BRAFi/MEKi resistance. In inhibitor-resistant melanoma cells 
with BRAF V600E mutation there is a type-β platelet-derived 
growth factor receptor (PDGFRβ) over-expression, but other 
changes in these cells are also present. There is also an incre-
ased activation of the IGFR1 receptor (a receptor of insulin – like 
growth factor 1), which leads to activation of the PI3K-AKT-
-mTOR pathway. Finally, in some resistant cells, elevated levels 
of epidermal growth factor receptors are also found [2]. From 
the physiological point of view, in general, it is always about 
reactivation of the signalling pathway transmitting information 
about proliferation. It is not possible to determine the cause 
of the drug resistance in all cases.
Some causes of BRAFi/MEKi drug resistance are related to 
the BRAF gene itself. However, these are not typical mutations 
in the gene itself that change its structure, but those that cause 
changes in the splicing of the gene transcript. The result is 
a  protein product again capable of forming dimers (which 
removes the activity of inhibitors that act on the monomer) or 
over-expression of this gene, resulting in more protein product 
that may result in the presence of dimers. Indirectly, RAS gene 
mutations can also influence dimerization [6].
Mechanisms of primary resistance of melanoma 
to treatment with BRAF inhibitors
Malignant melanomas are genetically very heterogenous. 
Moreover, they gain new mutations in the course of the me-
tastasis process [13]. A significant proportion of melanoma 
tumor cells carry the BRAF V600E mutation and about 20% of 
patients with melanoma with this BRAF V600E mutation do not 
respond to treatment with BRAF inhibitors [14]. In addition, 
different cancer cells in the same patient may carry different 
mutations responsible for resistance to BRAF inhibitors [6]. The 
main proposed mechanisms of primary resistance to BRAF 
inhibitors, such as PTEN loss, RAC1P292S mutation, MAP3K8 
over-expression, hepatocyte growth factor (HGF) secretion 
by stromal cells, NF1 suppressor gene loss and CCND1 ampli-
fication, are summarized in table I. 
Future studies should provide a more detailed explanation 
of the mechanisms underlying the BRAF inhibitor resistance 
and the discovery of common mechanisms of resistance to 
different groups of chemotherapeutic agents. An important 
objective of the studies is to identify biomarkers of primary 
resistance to BRAF inhibitors so that the therapeutic response 
can be predicted before the onset of the therapy.
Loss of the PTEN gene
The PTEN (phosphatase and tensin homolog) gene is a sup-
pressor gene – the protein encoded by this gene (phosphati-
dylinositol-3,4,5-trisphosphate 3-phosphatase – PTEN, MMAC1) 
is involved in cell cycle regulation. PTEN catalyzes PIP3 pho-
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sphorylation in the 3’ position of the inositol ring, which results 
in inhibition of the PI3K/AKT signalling pathway and finally 
inhibition of cell proliferation. The loss of the functional PTEN 
gene occurs in over 10% of melanoma cases and is one of 
the most common mutations responsible for BRAF inhibitor 
resistance [15]. Loss of PTEN expression leads to constitutive 
activation of the PI3K/AKT signalling pathway, which results 
in cell proliferation, cell growth and inhibition of apoptosis. 
The mechanism of resistance to BRAF inhibitors is inhibition 
of apoptosis induced by BIM protein (BCL2L11) [15]. 
RAC1P29S  gene mutation
RAC1 protein (rac family small GTPase 1 cell migration-inducing 
gene 5 protein) is a GTPase, a regulator of the cell cycle, cellular 
adhesion, cell mobility (by interacting with the cytoskeleton) 
and cell differentiation. The P29S mutation in the RAC1gene, 
according to Watson and Li [16] study results, occurs in 3.3% 
of cases of melanoma, so not very often. The presence of this 
mutation positively correlates with the mitotic index, the size 
of the lesion, as well as the occurrence of metastases [16]. 
However, the P29S mutation occurs in up to 20% of patients 
who do not respond to treatment with BRAF inhibitors [17]. 
Moreover, the presence of this mutation in melanoma cell lines 
causes resistance to BRAF inhibitors [16].
 MAP3K8 gene over-expression
The MAP3K8 gene codes for the MAP3K8 protein (mitogen-
-activated protein kinase kinase kinase 8, otherwise COT, EST, 
ESTF, MEKK8, TPL2, Tpl-2, c-COT, AURA2). The MAP3K8 protein 
can activate the MAPK/ERK signalling pathway. Increased level 
of COT protein results in maintenance of proliferation despite 
BRAF inhibition. In the case of primary over-expression of 
MAP3K8, administration of BRAF inhibitors leads to even higher 
COT production and, as a result, to further intensification of 
proliferation [18, 19]. MAP3K8 gene modifications occur in 
about 1.5% of all patients with melanoma, often (in about 33% 
of cases) they are present in Spitz nevi [20].
Loss of NF1 protein function
The NF1 gene encodes the neurofibromin protein (neurofi-
bromin or neurofibromatosis-related protein – NF-1), which 
belongs to the group of proteins that activate GTPases. Neu-
rofibromin is a negative regulator of RAS, the first protein of 
the MAPK signalling pathway. The loss of the functional NF1 
gene product means an increase in RAS protein level and 
activation of the MAPK pathway, also in the presence of BRAF 
inhibitors. The loss of NF1 causes resistance to RAF, MAPK and 
BRAF inhibitors through constitutive activation of the MAPK 
kinase signalling pathway [21].
CCND1 gene amplification
The CCND1 gene (BCL1) codes for cyclin D1(cyclin D1 or other-
wise B-cell lymphoma 1 protein), the key protein responsible 
for cell cycle regulation (G1/S phase transition). BRAFi resistan-
ce due to CCND1 amplification is an example of BRAF inhibitor 
resistance associated with gene copy number change. In cells 
where the CCND1 gene was amplified, increased production of 
cyclin D1 occurs and as a result BRAF inhibition is not sufficient 
to inhibit proliferation [22]. Amplification of CCND1 is observed 
in more than 38% of melanoma samples, which indicates that 
a large group of patients is potentially resistant to BRAFi and 
could benefit from CDK4/6 inhibitor therapy [23, 24].
Secretion of the hepatocyte growth factor by the 
stromal cells
The hepatocyte growth factor (HGF) is a factor responsible for 
cell growth, mobility and morphogenesis. Pleiotropic activity 
of HGF occurs through its receptor, a transmembrane tyrosine 
kinase, encoded by the cMet proto-oncogene. An example of 
a mechanism of primary resistance to BRAF inhibitors, which 
Table I. The most important mechanisms of primary resistance to BRAF inhibitors
Mutation/ other cause of 
resistance 
Proposed mechanism Bibliography
CCND1 amplification The CCND1 gene codes cyclin protein D1 – the key regulator of the cell cycle. Amplification 
of the CCND1 gene and increase of cyclin D1 protein level maintain cell proliferation in the 
presence of BRAF inhibitors.
[22, 23]
 RAC1P292S mutation RAC1P292S mutation maintains MAPK signalling pathway transmission in the presence of BRAF 
inhibitors, proliferation persists despite BRAF inhibition.
[16, 51]
MAP3K8 over-expression The MAP3K8 gene encodes the COT protein that activates the MAPK/ERK signalling pathway. 
Increased level of COT protein results in maintenance of proliferation despite BRAF inhibition. 
[18, 19]
Loss of the NF1 suppressor gene NF1 is the negative regulator for the RAS signalling pathway. Mutation of NF1 resulting in 
loss of functional neurofibromin 1 protein (NF1) causes an increase in RAS level, activation 
of CRAF and consequently activation of MAPK pathway, which results in maintenance of 
proliferation in the presence of BRAF inhibitors. 
[21, 52]
Loss of the PTEN gene PTEN is the PI3K/AKT pathway suppressor. Loss of PTEN results in constitutive activation of 
this signalling pathway and enables cell proliferation even in the case of BRAF inhibition. 
[15]
Secretion of hepatocyte growth 
factor (HGF) by stromal cells
HGF secretion leads to activation of the HGF receptor – MET – and activation of the MAPK/
ERK and PI3K/AKT.
[25, 26]
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is associated with the interaction of the tumor microenviron-
ment, is HGF secretion by the stromal cells (including fibro-
blasts). HGF secretion leads to activation of the HGF receptor 
– MET protein – and activation of the MAPK/ERK and PI3K/ 
/AKT pathways (fig. 2). Their activation results in maintenance 
of proliferation in the presence of BRAF inhibitors [25, 26]. 
Mechanisms of secondary resistance of 
melanoma to treatment with BRAF inhibitors
During treatment, most patients develop secondary resistance 
to BRAFi/MEKi. The most frequent mechanism of secondary 
resistance to BRAFi/MEKi treatment is connected with reacti-
vation of signal transduction through the MAPK/ERK pathway. 
Activation of this pathway may result from both the action of 
BRAF activating proteins activated by BRAF protein and the 
secondary activation of BRAF itself. 
Reactivation of signal transduction by MAPK/ 
/ERK 
Reactivation of signal transduction from the cell membra-
ne to MAPK/ERK kinases (upstream reactivation) is a result of 
over-expression of receptors tyrosine kinases, which leads to 
cell division by activating ARAF and CRAF kinases in place of 
BRAF. Melanoma cells with the BRAF mutation V600E during 
treatment with BRAFi/MEKi can develop treatment resistance 
by switching the signal to different RAF isoforms (ARAF, BRAF 
or CRAF) and the resulting reactivation of transmission within 
the ERK pathway [14]. In melanoma cells there may be over-
-expression of ARAF or CRAF proteins while BRAF is blocked. 
ERK protein is a negative regulator of RAS protein. The BRAF 
inhibitor inhibits the growth of neoplastic cells by inhibiting 
the ERK pathway. The signal transduction blockage through 
the ERK  pathway stops RAS regulation, inducing partial RAS 
activity. Activation of RAS leads to the creation of BRAF V600E 
dimers. BRAF inhibitors bind to one of the monomers, leading 
to the transactivation of the second monomer, not bound by 
the drug. Such activation of BRAF results in partial activation 
of signal transduction and contributes to the reduction of 
treatment efficacy [27, 28]. 
The MAPK/ERK signalling pathway may also be activated 
by the accumulation of activating mutations in the RAS gene 
as RAS promotes cell division by phosphorylating the ARAF 
and CRAF proteins to compensate for BRAF inhibition. After 
binding GTP, mutant RAS protein does not dissociate to an 
inactive form associated with GDP and is constantly activated. 
The PGD-related mutant RAS protein associated with PGD also 
promotes BRAF V600E dimerisation, reactivation of the ERK 
signalling pathway and ultimately influences the formation 
of resistance to BRAF inhibitors, as these drugs are exclusively 
associated with BRAF V600E monomers [29–31]. 
BRAF
Figure 2. Activation of signalling transduction pathways in the development of drug resistance to BRAFi/MEKi
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Activation of signal transduction below MAPK/ 
/ERK proteins 
The activation of signal transduction to target genes by the 
RAS-RAF-MEK-ERK signalling pathway can occur due to acti-
vating mutations in the genes for MEK1/MEK2 (mitogen-acti-
vated protein kinase 1/2) proteins. As a result of the activation 
of MEK proteins (downstream reactivation), the initiation of 
the signal transfer at the BRAF  level is no longer necessary 
for the activation of target genes, thus eliminating the effect 
of BRAF inhibition [6].
BRAF protein reactivation  
Reactivation of BRAF protein function may occur by many 
mechanisms, among which amplification of the mutant BRAF 
allele is frequent. The BRAF protein is over-expressed due to 
an increase in the number of gene copies. As a result of the 
presence of very many copies of BRAF protein in the cell, the 
inhibitor dose (the number of inhibitor molecules in the cell) 
is no longer sufficient (in proportion) to inhibit their activity. 
Increasing the amount of mutant BRAF V600E protein results 
from increasing the number of gene copies and may lead to 
spontaneous dimerization of this protein, reactivation of the 
ERK signalling pathway and become a cause of drug resistance. 
This type of resistance has been defined as dose-dependent. 
In in vitro studies, higher doses of vemurafenib lead to over-
coming drug resistance [32]. 
In addition, the BRAF V600E variant, which is produced 
by alternative splicing of p61BRAF V600E, has been descri-
bed in patients with secondary resistance to vemurafenib. 
This variant forms dimers independently of activation by RAS 
kinase, which makes BRAF inhibition ineffective, due to the 
above-mentioned BRAFi activity only towards BRAF V600E 
monomers. Alternative BRAF splicing isoforms appear to be 
formed as a result of mutations or epigenetic changes [33, 34]. 
PI3K/AKT signalling pathway activation 
The PI3K/AKT signalling pathway communicates with the ERK 
pathway, and inhibiting one pathway can cause the other to 
become more active (figure 2). Blocking ERK signaling can 
lead to an adaptive PI3K/AKT overactivity that compensa-
tes for BRAF inhibition and drives resistance. Abnormal PI3K/
AKT signaling is a common feature of melanoma and causes 
resistance by stimulating alternative pathways that reduce 
dependence on ERK signaling. Mutations leading to increased 
activity of the PI3K/AKT pathway were identified in 22% of 
melanomas with acquired BRAF inhibition resistance. It was 
shown that within a few days after the administration of BRAF 
inhibitors the expression of AKT protein was increased [35–37].
In preclinical studies it was initially hypothesized that 
during BRAFi/MEKi treatment there was a strong selection 
pressure on cells with gain of function mutations leading to 
increased PI3K/AKT pathway activity in the presence of MAPK 
pathway inhibition. It was assumed that melanoma cells with 
such mutations will divide, because they have an advantage 
in terms of survival and proliferation when their metabolism is 
not affected by BRAF inhibition. In clinical observations, it is this 
intensive proliferation of cells with an activated AKT pathway 
that may explain the presence of high tumor mass and rapid 
progression in patients who responded to BRAF inhibition and 
then developed secondary resistance by this mechanism. Ad-
ditionally, the PI3K/AKT pathway is activated by growth factors 
that are associated with RTK, such as PDGFR-β and IGF-1R. 
When BRAF is blocked by an inhibitor, tumor cells may incre-
ase the expression of PDGFR-β and IGF-1R in a compensatory 
manner. This in turn leads to a persistent PI3K/AKT signaling 
that prevents apoptosis and promotes cell survival. Activated 
AKT phosphorylates as many as 9000 substrate proteins, thus 
regulating various processes such as cell survival, proliferation 
and migration, and affecting drug resistance. 
The AKT substrate proteins include molecules such as: 
ASK1 (apoptotic signal kinase 1), Bim (B cell leukemia/lym-
phoma-2 interacting mediator of cell death), Bad (B cell leuke-
mia/lymphoma-2 associated death agonist), MDM-2 (murine 
double minute-2), p21(p21 cyclin dependent kinase protein 
inhibitors, Cip1), XIAP (X-linked inhibitor of apoptosis), Foxo3a 
(forkhead box O3) and many others [38]. High expression of the 
above mentioned RTK receptors on the surface of melanoma 
cells is associated with acquired resistance to vemurafenib 
both in vitro and in vivo. In addition, PI3K and AKT activating 
mutations can increase the signal strength of the AKT signalling 
pathway. This in turn intensifies the anti-apoptotic signals and 
the regulation of expression of the most important proliferative 
genes described above. These changes allow melanoma cells 
to survive and replicate independently of BRAF inhibition, 
which clinically causes the acquired resistance [6, 37, 39]. 
Increased activation of the EGFR signalling 
pathway 
Increased expression and activation of the epidermal growth 
factor receptor (EGFR) may also be associated with BRAF or MEK 
inhibition resistance. Once activated, the EGRF complex formed 
by Grb2 and Sos proteins binds directly or by combining Shc 
adaptor protein with specific tyrosine residues on the receptor. 
This leads to conformational changes in the Sos protein, which 
can recruit and activate Ras-GDP. Then ERK-activated MAPK kinases 
eventually move to the nucleus to induce cell proliferation by 
phosphorylating specific transcription factors such as Elk1 and 
C-myc, [40]. Reduced SOX10 (sex determining region Y-box 10) 
activity described in some melanomas may lead to signaling via 
TGF-β and consequently to increased expression of EGFR receptor 
gene and platelet-derived growth factor receptor (PDGFRB) [6, 41]. 
Tumor microenvironmental activation
The research on drug resistance focuses mainly on the me-
chanisms of drug resistance, which are a result of changes 
in the properties of cancer cells. It is now known, however, 
139
that disease progression and resistance to targeted BRAFi/
MEKi therapies are not exclusive derivatives of genomic and 
epigenetic cancer cell modifications. 
The microenvironment of the tumor promoting MAPK inhi-
bition resistance is important and this relationship is complex 
and includes interactions between the tumor and stromal cells, 
among others [42]. Recent studies have shown that macropha-
ges and factors derived from fibroblasts clearly contribute to 
the development of resistance to MAPK pathway inhibitors. 
In the presence of fibroblasts, the adjacent melanoma cells 
acquire a differentiated, aggressive mesenchymal phenotype. 
After BRAFi treatment, these melanoma cells maintain a high 
level of phosphorylated ribosomal protein S6 (pS6), and thus 
active signaling through mTOR, which is suppressed in BRA-
Fi-sensitive cells without contact with the stromal cells [43]. 
Activation of mTOR leads to phosphorylation and activation 
of the ribosomal kinase S6 p70 and eukaryotic protein binding 
factor 4E 1E, thus promoting increased protein translation and 
cell growth. mTOR is a kinase that links cell stimulation with 
growth factors and nutrient availability with protein synthesis 
and cell growth [44].
In recent years it has been estimated that fibroblasts fa-
cilitate melanoma progression and two-way communication 
exists through direct contact between melanoma cells and 
fibroblasts. Additionally, melanoma cells respond to fibroblast’ 
secretion of growth factors and cytokines promoting cell su-
rvival and growth, including TGF-β and VEGF. Fibroblasts in 
contact with melanoma cells also release extracellular matrix 
components (e.g. laminin IV), which facilitate secondary migra-
tion (metastasis) of melanoma cells [45, 46]. Within the tumor, 
fibroblasts show hyperactivation of the MAPK pathway, which 
results in a qualitative change in the extracellular matrix of the 
tumor by β1 integrin and FAK kinase, which induce ERK, ensu-
ring that melanoma cells can avoid effective treatment [47].
In melanoma, as a result of HGF secretion by stromal cells, 
resistance to BRAFi/MEKi may develop. HGF may bind RTK on 
the surface of melanoma cells, which will increase intracellular 
signaling promoting RAS expression, which ultimately leads to 
activation of the MAPK pathway. Moreover, it is known that HGF 
contributes to the development of resistance to BRAF inhibitor 
treatment by reducing the expression of genes encoding pro-
-apoptotic factors [25, 26]. 
The influence of fibroblasts on melanoma cells may differ 
significantly in elderly patients, because aging fibroblasts are 
more invasive. Recent studies have shown that aging fibro-
blasts increase the secretion of the sFRP2 factor – β-catenin 
inhibitor – which reduces the expression of MITF, leading to 
reduced expression of the APE1 redox regulator and makes 
melanoma cells more sensitive to oxidative stress, thus pro-
moting secondary resistance to BRAF inhibition [48]. 
Macrophages of the tumor stroma secrete TNF-α factor, 
which promotes MITF expression depending on NF-β, which 
leads to BRAFi/MEKi resistance. Additionally, TNF-α has been 
proven to block apoptosis in cells in which BRAF is inhibited 
and to contribute to melanoma invasion and angiogenesis 
[49, 50]. 
Summary
The main mechanisms of resistance to BRAF inhibitors are:
1. Loss of inhibitory function of ERK kinase – BRAF inhibitor 
inhibits tumor growth by inhibiting the ERK pathway. This 
secondarily inhibits ERK negative feedback to RAS, which 
partially restores RAS activity. It leads to the formation of 
BRAF V600E dimers induced by RAS. BRAF inhibitors bind 
one and transactivate the other activate the other BRAF, 
reducing the effectiveness of BRAF inhibitor treatment. 
2. Mutations activating the RAS gene – mutated RAS-GTP 
becomes constitutively active, increases BRAF V600E di-
merization, reactivates the ERK pathway and secondarily 
promotes resistance to BRAF inhibitors that block only 
monomeric BRAF V600E.
3. Alternative splicing of BRAF V600E – the BRAF V600E spli-
cing variant due to mutations or epigenetic changes can 
form dimers independently of RAS. This makes the BRAF 
inhibitor ineffective because it blocks only the monomeric 
BRAF V600E.
4. Over-expression of mutant protein BRAF V600E – an incre-
ased number of BRAF V600E copies in a cell (due to gene 
copy number increase) may also spontaneously favor BRAF 
V600E dimerization, reactivating the ERK pathway and 
causing treatment failure in some patients.
5. Activation of alternative RAF protein isoforms – BRAF V600E 
melanoma treated with BRAF inhibitors can acquire resi-
stance by flexible switching between different RAF iso-
forms capable of reactivating the ERK pathway, increasing 
expression of ARAF or CRAF.
6. The over-expression of COT-COT protein, probably due 
to gene amplification or yet unidentified mechanisms, 
may reactivate MEK in the presence of BRAF inhibition, 
stimulating ERK signaling and drug resistance to BRAFi. 
7. Mutations activating the MEK gene – mutations activating the 
MEK1/MEK2 gene make blocking the BRAF ineffective, becau-
se reactivation of MEK means that the MAPK/ERK pathway can 
still transmit a signal below BRAF, regardless of its inhibition.
8. Activation of the PI3K/AKT signalling pathway. Incorrect 
PI3K/AKT signaling is a frequent feature of melanoma. 
Blocking ERK signaling can lead to an adaptive PI3K/AKT 
overactivity that compensates for BRAF inhibition and 
promotes resistance. 
9. Receptor tyrosine kinase (RTK) activation – the PI3K/AKT 
pathway is activated by growth factors that are associated 
with RTK, such as PDGFR-β and IGF-1R. With the BRAF block, 
cancer cells can over-express RTK, leading to permanent 
PI3K/AKT signaling. 
10. Activating mutations in PI3K/AKT genes – activating muta-
tions in  PI3K/AKT and AKT amplify AKT signaling, which in-
140
creases anti-apoptotic signals and increases the expression 
of key proliferative genes, providing the cell with survival 
signals independent of BRAF. 
11. EGFR signal path activation – EGFR activation induced by 
SOX10 suppression and increased TGF-β pathway activity 
that causes cell ageing is reversed by BRAF/MEK inhibition.
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